PharmaTimes October 9, 2025
John Pinching

New MHRA–FDA collaboration aims to boost patient access and AI safety

Patients in the UK are set to benefit from a strengthened partnership between the Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA), as both regulators unveil new plans to accelerate access to cutting-edge medical technologies and artificial intelligence in healthcare.

Announced at the Advanced Medical Technology Association (AdvaMed) conference in San Diego, MHRA Chief Executive Lawrence Tallon outlined the agency’s commitment to deepening ties with the FDA and driving global regulatory harmonisation.

Tallon said: “We continue to work in close collaboration, and are taking steps forward in the relationship between FDA and MHRA to strengthen regulatory alignment and reciprocity. We share an...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: AI (Artificial Intelligence), Conferences / Podcast, FDA, Govt Agencies, Technology, Trends
Related Articles:
FDA guidance eases wearables oversight. But experts have questions about what’s next.
AI Model FDA-Cleared to Triage 14 Conditions
The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 2)
FDA Updates Two Digital Health Final Guidance Documents
FDA in Flux — January 2026 Newsletter

Share Article